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Open access undA multi-compartment physiologically based pharmacokinetic (PBPK) model was developed to describe
the behavior of Cr(III) and Cr(VI) in rats and mice following long-term oral exposure. Model compart-
ments were included for GI lumen, oral mucosa, forestomach/stomach, small intestinal mucosa (duode-
num, jejunum, ileum), blood, liver, kidney, bone, and a combined compartment for remaining tissues.
Data from ex vivo Cr(VI) reduction studies were used to characterize reduction of Cr(VI) in fed rodent
stomach ﬂuid as a second-order, pH-dependent process. For model development, tissue time-course data
for total chromium were collected from rats and mice exposed to Cr(VI) in drinking water for 90 days at
six concentrations ranging from 0.1 to 180 mg Cr(VI)/L. These data were used to supplement the tissue
time-course data collected in other studies with oral administration of Cr(III) and Cr(VI), including that
from recent NTP chronic bioassays. Clear species differences were identiﬁed for chromium delivery to
the target tissue (small intestines), with higher concentrations achieved in mice than in rats, consistent
with small intestinal tumor formation, which was observed upon chronic exposures in mice but not in
rats. Erythrocyte:plasma chromium ratios suggest that Cr(VI) entered portal circulation at drinking water
concentrations equal to and greater than 60 mg/L in rodents. Species differences are described for distri-
bution of chromium to the liver and kidney, with liver:kidney ratios higher in mice than in rats. Overall,
the PBPK model provides a good description of chromium toxicokinetics, with model predictions for tis-
sue chromium within a factor of 3 for greater than 80% of measurements evaluated. The tissue data and
PBPK model predictions indicate a concentration gradient in the small intestines (duodenum > jeju-
num > ileum), which will be useful for assessing the tumor response gradient observed in mouse small
intestines in terms of target tissue dose. The rodent PBPK model presented here, when used in conjunc-
tion with a human PBPK model for Cr(VI), should provide a more robust characterization of species dif-
ferences in toxicokinetic factors for assessing the potential risks associated with low-dose exposures of
Cr(VI) in human populations.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Hexavalent chromium [Cr(VI)] has recently been shown to
cause small intestinal tumors in mice, and oral cavity tumors inlumen Cr concentration; Cr,
lent chromium; GI, gastroin-
estines section length; PBPK,
tive absorption; SDD, sodium
al rate.
C.R. Kirman).
er CC BY-NC-ND license.rats following chronic exposure to high concentrations of Cr(VI)
in drinking water [1,2]. Although Cr(VI) is known to cause lung
cancer due to occupational exposures in certain industries, and
also induces respiratory tumors in animals following inhalation
and intrabronchial administration [3], oral exposure to Cr(VI)
was not thought to pose a cancer hazard previously because Cr(VI)
is largely detoxiﬁed by reduction to trivalent chromium [Cr(III)] in
the acidic reducing conditions of the stomach [4,5]. Thus, observa-
tion of gastrointestinal (GI) tract tumors in rodents exposed to very
high concentrations of Cr(VI) in drinking water raises several
important questions regarding the toxicokinetics of ingested
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the stomach was overwhelmed by the high concentration expo-
sures and how the toxicokinetics of Cr(VI) differ between humans
and rodents [6–8]. Further, species differences in toxicokinetics
may inform the mode of action (MOA) for carcinogenesis, and
quantitative descriptions of the toxicokinetics may be used in PBPK
modeling to reﬁne extrapolation of target tissue dose between spe-
cies and over the range of doses of interest for risk assessment [6].
Humanexposure to lowconcentrations of Cr(VI) is nowknown to
be widespread. Cr(VI) occurs at relatively low concentrations in
drinking water throughout the United States [12,24], and in other
locations around the world [9,10]. Although the occurrence of high
concentrations of Cr(VI) in environmental media is typically due to
industrial pollution, most low level Cr(VI) in drinking water is be-
lieved to occur from natural sources associated with Cr-enriched
geology [9,11,12]. Cr(VI) has also been reported at low levels in
urban household dust [7] and in some foods [13,14]. For these rea-
sons, the cancer risk assessment of ingested Cr(VI) at environmen-
tally-relevant exposures is of signiﬁcant public health interest.
The dose–response for small intestinal tumors in the NTP bioas-
say for mice has been the basis of several health risk assessments
of oral Cr(VI) exposure in humans [7,15,16]. In these assessments,
however, default procedures for extrapolating between species
(body weight scaling of dose to the 3=4 power) and across dose
(assumptions of linearity) were applied because rodent- and hu-
man-speciﬁc PBPK models that include parameterization of the
gastrointestinal (GI) were unavailable. In these assessments, the
tumor incidences for mouse duodenum, jejunum, and ileum were
summed to estimate cancer potency based on administered dose
without consideration of the longitudinal gradient in hyperplasia/
tumor response, and likely differences in tissue dose by segment.
Speciﬁcally, the strongest response was observed in mouse duode-
num, a weaker response was observed in mouse jejunum, and a re-
sponse was generally absent in mouse ileum, consistent with a
gradient for portal of entry effect with decreasing target tissue
dose with distance from the stomach.
Earlier PBPK models for Cr(VI) and Cr(III) have been developed
for rats and humans [17,18], but they do not include parameteriza-
tion of the GI tract. While these models potentially provide a valu-
able starting point for estimating kinetics of Cr(VI) and Cr(III), they
were parameterized with very little oral dosing data. In fact, many
kinetic parameters in the model were estimated using PK data from
studies that utilized a single intra-tracheal administration of Cr(VI).
Until the NTP cancer studies, the PK data following chronic oral
exposures to Cr(VI) was fairly limited, particularly in mice.
The work presented here is part of multifaceted research effort
to provide the data and tools needed to support Cr(VI) risk assess-
ment. The study was designed using US EPA risk assessment guid-
ance [22] and to address data gaps in the hypothesized mode of
action (MOA) for Cr(VI) in mouse small intestines [6]. To date,
these efforts have resulted in publications on the reduction of
Cr(VI) in rodent gastric contents [21], analysis of toxicogenomic
responses in rodent small intestines [70,71], and evaluation of bio-
chemistry and histopathology in mouse and rat oral mucosa and
small intestine [19,20]. The current study incorporates ex vivo data
collected for the rate and capacity of Cr(VI) reduction in fasted
rodent gastric contents [21]. In addition, a PBPK model is under
development for Cr(III) and Cr(VI) in humans based upon the
ex vivo reduction data and toxicokinetic data from the published
literature (in prep). The model will be used to support quantitative
risk assessment for oral exposures to Cr(VI) by: (1) improving
extrapolations across species (i.e., from rodents to humans); (2)
improving extrapolations from the high-dose exposures associated
with tumors in rats and mice to low-dose environmentally-rele-
vant exposures; (3) characterizing dose gradients in the small
intestines that may help explain the response gradient for tumorformation in mice; and (4) characterizing target tissue doses in
term of speciated forms of chromium [Cr(III) or Cr(VI)] rather than
relying upon measurements of total chromium in tissues or upon
administered dose. PBPK modeling is the preferred method for in-
ter-species extrapolation because it offers a more robust approach
as compared to default procedures such as allometric scaling (e.g.,
body weight raised to the 3=4 power) and assumptions of linear
toxicokinetics [19,22,23]. Improving high-to-low dose extrapola-
tion is particularly important because Cr(VI) drinking water
concentrations that induced tumors in rodents (P20 mg Cr(VI)/L)
are more than 1000-times higher than typical drinking water
concentrations of Cr(VI) to which humans are exposed
(0.001–0.005 mg Cr(VI)/L) [12,24].2. Materials and methods
The published literature for chromium was reviewed to: (1)
identify important toxicokinetic processes needed to develop a
conceptual model; (2) identify key data sets that can be used to
support development of a PBPK model; and (3) identify important
data gaps for chromium toxicokinetics. With respect to the latter,
the NTP cancer bioassays for chromium include tissue time-course
data for total chromium [1,25]; however because the small intes-
tines and oral cavity were not identiﬁed as target tissues prior to
the completion of the Cr(VI) bioassay, concentration data for these
tissues were not collected. To supplement these data, two 90-day
drinking water studies were conducted for Cr(VI) in female F344
rats and B6C3F1 mice (i.e., the species and strains used in the
NTP bioassays) to quantify total chromium in target tissues. Be-
cause the dose–response relationships for tumors appear similar
in male and female animals, and because there is no reason to
anticipate sex differences in chromium toxicokinetics, tissue mea-
surements in both sexes were not required. Details pertaining to
the conduct of these studies are described elsewhere [19,20]. In
brief, animals were exposed to Cr(VI) in drinking water for 90 days
at concentrations similar to those in the NTP cancer bioassay (5–
180 mg Cr(VI)/L) and two lower concentrations (0.1 and 1 mg
Cr(VI)/L) as SDD. Target tissue concentration data in the low-dose
range should provide internal dose information around the point
of departure for characterizing cancer potency. Chromium cannot
be speciated in tissues, and thus total chromium content was
determined in the following tissues: oral mucosa, duodenum, jeju-
num, ileum, stomach, plasma, erythrocytes, and liver. Because ani-
mals in the NTP cancer bioassay became anemic [1], and because
there are potential interactions between the toxicokinetic pro-
cesses for chromium and iron, iron content was also determined
in the same set of tissues. Tissue chromium and iron concentra-
tions were ﬁrst tested for dose-related trends using Jonckheere’s
test [26]. Datasets with a signiﬁcant trend were then analyzed by
Williams’ (parametric) or Shirley’s tests (nonparametric) [27],
whereas Dunnett’s (parametric) or Dunn’s (non-parametric) tests
were run if a monotone trend was not observed. Statistical tests
were performed using the open-source, programming language, R
(http://www.R-project.org). Additional data were collected to sup-
port model development for the ex vivo reduction of Cr(VI) in gas-
tric contents. The methods and results for this study are described
elsewhere [21,28].
Code for the PBPK model was developed to describe the key tox-
icokinetic processes identiﬁed in the conceptual model. All PBPK
modeling was performed in acslX along with its interface for Excel
(Aegis TG, version 3.0). Model parameter values were set based on:
(1) data from the published literature; (2) by adjusting parameter
values to obtain ﬁts to the key data sets identiﬁed in Step 1; and (3)
professional judgment. Data from the published literature in
contained within ﬁgures were converted to numerical values using
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to modeling the chromium data sets involved ﬁrst deﬁning model
parameter values for Cr(III), then holding the Cr(III) parameters
and Cr(VI) reduction parameters ﬁxed [28], the Cr(VI) model
parameters were adjusted to obtain ﬁts to the key data sets iden-
tiﬁed for Cr(VI). Code was included in the model to track chromium
mass-balance (see Appendix B) and all model simulations were
checked to ensure mass-balance was maintained. Model parame-
ters were deﬁned in both species using the following sequence:
(1) parameters describing the ﬂux of Cr(III) through GI tissues;
(2) parameters describing Cr(III) in systemic tissues and excreta;
(3) parameters describing the ﬂux of Cr(VI) through GI tissues;
and (4) parameters describing Cr(VI) in systemic tissues. Optimiza-
tions were used in a supportive manner, and were performed for
each data set using acslX Optimum to inform the selection param-
eter values. However, optimized values were not necessarily
adopted for the ﬁnal model, since emphasis was placed on predict-
ing the behavior of the toxicokinetic data rather than obtain the
best statistical ﬁt (e.g., see discussion of ﬁt to the blood data of
Thomann et al. [30] below). Optimizations conducted for each data
set were performed by maximizing the log-likelihood function
using the NelderMead algorithm, with upper and lower bounds de-
ﬁned for optimized parameters as a factor of 3 higher and lower
than the value obtained by visual inspection. If either bound was
encountered in during interim optimization results, the bound
was relaxed by an additional factor of 3 and the optimization
was rerun. In cases where the NelderMead algorithm failed to con-
verge, the optimization was rerun using alternative algorithms
(NL2SOL, particle swarm) that exhibit better convergence when
parameters are far from their optimum. Heteroscedasticity param-
eters were set equal to one for the likelihood error model. The NTP
[29] data sets for rats and mice exposed to SDD in drinking water
for 21 days were not used to estimate model parameters, but were
instead held back to be used for model validation purposes. The
overall ﬁt of the rat and mouse models was assessed by identifying
the percentage of model predictions that fall within a factor of 3 of
measured data points. Sensitivity analyses were conducted for
both rodent models by adjusting model parameter values individ-
ually by 5% and then reporting the relative impact on several
predicted measures of internal dose.3. Theory
3.1. Key data sets
The toxicokinetics of chromium (III and VI) in systemic tissues
have been fairly well studied. Information regarding the absorp-
tion, reduction, distribution, and excretion of chromium in rodents
was reviewed to identify key processes, sources of saturable toxic-
okinetics, and species differences. For the purpose of identifying
tissue concentration data sets to compare to PBPK model predic-
tions, preference was given to identifying data sets that provide tis-
sue levels in rats and mice following long-term oral exposure
(Table 1). Studies involving inhalation exposures to chromium or
non-environmental routes of exposure (intravenous injection,
intraperitoneal injection, intratracheal instillation), while also
available, were generally not needed for model development be-
cause sufﬁcient long-term oral studies were identiﬁed.
The absorption of a single gavage dose of Cr(III) (as chromium
picolinate in aqueous solution) in rats was reported to be approx-
imately 1.1–1.5%, based upon cumulative urinary excretion within
48 h after dosing [25]. Once absorbed, the liver, kidney and bone
serve as the primary storage depots for systemic chromium
[1,25,30–32]. Due to its relatively poor absorption, most of
ingested chromium is excreted in the feces. Chromium that isabsorbed is primarily excreted in the urine [1,25,33,34,35,36].
Inspection and evaluation of the tissue concentration data for the
key data in rats and mice following repeated exposures to chro-
mium (Table 1) reveal three important patterns:
1. The concentration ratio for chromium in erythrocytes:plasma
serves as a potential biomarker for systemic Cr(VI) absorption.
Under normal (background) conditions, exposures to Cr(III),
and low-dose exposures to Cr(VI), this concentration ratio is
generally less than one. For example, the erythrocyte:plasma
ratio for all treatment groups of rats and mice exposed to chro-
mium picolinate in the diet was less than 1 [25]. However, with
doses sufﬁciently high enough to exceed the reduction capacity
of the GI lumen and tissues, Cr(VI) reaches portal plasma where
it is readily taken up by erythrocytes [37] and reduced to Cr(III)
[38]. Because Cr(III) is much less permeable to cell membranes
and is thought to bind to heme, absorbed Cr(VI) is reduced to
Cr(III) and effectively ‘‘trapped’’ within the erythrocyte. Cr(III)
levels in plasma are maintained at relatively low concentrations
due to effective transport to tissues (including erythrocytes),
and therefore this trapping of Cr(VI) results in erythro-
cyte:plasma chromium ratios that exceed unity. In rats exposed
orally to Cr(VI) via drinking water, this ratio is less than or equal
to 1 at low exposure levels (5 and 20 mg Cr(VI)/L), but becomes
greater than 1 at higher exposure levels (60 and 180 mg/L) [1].
Similarly in mice, the erythrocyte:plasma chromium ratio was
less than 1 in animals at low exposure levels (5 and 20 mg Cr/
L), but exceeds a value of 1 at higher exposures (60 or 180 mg
Cr/L) [1]. Interpretation of the plasma and erythrocyte data
from the NTP bioassay [1] is complicated by a 2-day depuration
period (i.e., period of no exposure while in metabolism cages for
2 days prior to sacriﬁce) because clearance of chromium differs
for these two compartments. Plasma chromium concentrations
likely decrease more rapidly than that in erythrocyte during the
washout period because the half-life of chromium in plasma is
much shorter than that in erythrocytes where chromium can be
bound to heme for the life of the erythrocyte.
2. The ratio of the chromium concentrations detected in liver and
kidney shows a relationship that is consistent for both Cr(III) (as
chromium picolinate in feed) and Cr(VI) (as sodium dichromate
in drinking water) exposures [1,25] (Fig. 1). The fact that this
relationship is maintained for exposures to either Cr(III) or
Cr(VI) suggests that systemic chromium following Cr(VI)
administration behaves the same as systemic chromium follow-
ing Cr(III) administration. This is best explained by the efﬁcient
reduction of Cr(VI) to Cr(III) either prior to absorption (i.e.,
within GI lumen) or shortly after absorption (i.e., within GI tis-
sue, portal blood, and to a lesser extent in the liver) prior to
reaching systemic circulation and other tissues.
3. There are clear and consistent differences between rats and
mice with respect to the systemic distribution of chromium in
tissues. Based upon the data collected by NTP [1,25], liver:kid-
ney ratios are consistently less than 1 (i.e., kidney Cr > liver
Cr; Fig. 1a) in rats, and are consistently greater than 1 in mice
(i.e., liver Cr > kidney Cr; Fig. 1b).
These three patterns for internal dose were used to inform the
development of the PBPK model below.
3.2. Conceptual model
A conceptual model for chromium toxicokinetics was developed
based upon a review of the data available from the published liter-
ature, and of the data collected in our 90-day drinking water stud-
ies. The conceptual model describes the key processes for Cr(VI)
starting from ingestion to excretion.
Table 1
Summary of key pharmacokinetic data sets for chromium in rats and mice.
Species Valence Cr form Exposure regimen Exposure levels
(doses in mg Cr/kg day)
Tissues [Reference]
Rat Cr(III) Picolinate Dietary exposure for 6, 13, or
182 days
0, 2000, 10,000, or 50,000 ppm diet
(0, 10.7, 54.9, 286)
Liver, kidney, plasma, erythrocyte, forestomach,
stomach, urine, feces [25]
Chloride Drinking water for 1 year 25 mg Cr/L (4.1) Liver, kidney, bone, spleen [31]
Cr(VI) Dichromate Drinking water for 6, 13, and
182 days
0, 5, 20, 60, or 180 mg Cr/L (0, 0.25,
0.98, 2.6, 7.4)
Liver, kidney, plasma, erythrocytes, forestomach,
stomach [1]
Dichromate Drinking water for 21 days 0, 1, 3, 10, 30, 100, or 300 mg Cr/L
(0, 0.11, 0.36, 1.2, 3.5, 11, 30)
Blood, kidney, bone [29]
Dichromate Drinking water for 90 days 0, 0.1, 1, 20, 60, 180 mg Cr/L (0,
0.015, 0.21, 2.9, 7.2, 20.5)
Oral cavity, stomach, duodenum, jejunum, ileum,
liver, plasma, erythrocyte [this study]
Chromate Drinking water for 42 days,
followed by 12 weeks of depuration
100 mg Cr/L (17) Liver, kidney, blood, spleen, bone, carcass [30]
Chromate Drinking water for 4 or 8 weeks 8 mg/kg day Blood, plasma, liver, kidney, spleen, bone, lung,
heart, muscle [32]
Mouse Cr(III) Picolinate Dietary exposure for 6, 13, or
182 days
0, 2000, 10,000, or 50,000 ppm (0,
28.6, 143, 728)
Liver, kidney, plasma, erythrocytes, forestomach,
stomach, urine, feces [25]
Cr(VI) Dichromate Drinking water for 6, 13, and
182 days
0, 5, 20, 60, or 180 mg Cr/L (0, 0.4,
1.6, 4.1, 10.4)
Liver, kidney, plasma, erythrocytes, forestomach,
stomach [1]
Dichromate Drinking water for 21 days 0, 1, 3, 10, 30, 100, or 300 mg Cr/L
(0, 0.4, 1.4, 3.2, 12.9, 23.8, 54.9)
Blood, kidney [29]
Dichromate Drinking water for 90 days 0, 0.1, 1, 3, 20, 60, 180 mg Cr/L (0,
0.024, 0.32, 1.1, 4.6, 11.6, 30)
Oral cavity, stomach, duodenum, jejunum, ileum,
liver, plasma, erythrocyte [this study]
Chromate Drinking water for 4 or 8 weeks 8 mg/kg day Blood, plasma, liver, kidney, spleen, bone, lung,
heart, muscle [32]
Fig. 1. Plots of liver vs. kidney concentration in rats and mice exposed to Cr(III) and Cr(VI) [1,25]: (A) Rat; (B) Mouse; solid lines reﬂect parity (i.e., liver concentration = kidney
concentration). X- and Y-axes are log-scale.
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Because GI tissues have been identiﬁed as target of Cr(VI) car-
cinogenicity in rats (oral cavity) and mice (small intestines), and
because a gradient is apparent for tumor response in the small
intestines (duodenum > jejunum > ileum) [1], an understanding
of the toxicokinetic processes in GI lumen and tissues is needed
to facilitate PBPK model development. Ingested Cr(VI) enters the
oral cavity, where it is subject to uptake into oral cavity tissue.
Although there may be some reduction of Cr(VI) by saliva in the
oral cavity, the transit time in the oral cavity is expected to be suf-
ﬁciently short (e.g., a few seconds) such that reduction in the oral
cavity lumen is likely to be negligible. In the rodent GI tract, the
forestomach serves as a place of storage, and as such helps main-
tain a consistent volume of GI lumen contents even during timesof fasting [39–41]. Cr(VI) reaching the stomach becomes mixed
with gastric ﬂuid, food, and water, and while in lumen of the stom-
ach and small intestines, it is subject to three competing processes:
(1) transit to more distal GI lumen sections (process R1 in Fig. 2);
(2) reduction to Cr(III) within the lumen (process R2a in Fig. 2);
and (3) uptake/absorption into GI tissue (process R3 in Fig. 2).
The reduction of Cr(VI) by stomach contents collected from ro-
dent stomach (forestomach and glandular stomach combined) has
been described as a pH-dependent, capacity limited, 2nd order pro-
cess dependent upon concentrations of both Cr(VI) and the native
reducing agents [21,28]. A longitudinal gradient is present within
the lumen of the small intestines with respect to pH. The pH of
the lumen is lower in the duodenum where it receives material
from the stomach, and generally increases as lumen material tran-
Fig. 2. Competing toxicokinetic processes for chromium in the gastrointestinal
tract: R1 = gastrointestinal transit; R2 = Cr(VI) reduction; R3 = Cr transport to
epithelium; R4 = Cr absorption into blood; R5 = Cr transit in portal plasma to the
liver; R6 = Cr in sloughed cells. Processes are depicted for a single section of the GI
tract, but are applicable to model compartments for the stomach, duodenum,
jejunum, and ileum in sequence.
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from bile, pancreatic ﬂuid, and intestinal secretions [39,42,43]. Be-
cause the reduction of Cr(VI) is pH dependent [28], the rate of
Cr(VI) reduction in the small intestinal lumen is expected to
change as a result of this pH gradient and is modeled as such.
Within the GI tissue, Cr(VI) is subject to further reduction (pro-
cess R2b in Fig. 2), while both forms of chromiummay be absorbed
into portal plasma (process R4 in Fig. 2) or returned to the GI
lumen due to cell sloughing (process R6 in Fig. 2). Sloughed cells
from the oral cavity and stomach are subject to digestion within
the stomach lumen, and therefore chromium contained within
these cells may be reabsorbed. Sloughed cells from the small intes-
tines are assumed to transit to the large intestines, and ultimately
are lost to fecal excretion. Absorption of Cr(III) and Cr(VI) is
expected to occur primarily within the small intestines. Although
some uptake of chromium into oral cavity and stomach are
expected, their contribution to systemic absorption of chromium
is expected to be small in comparison to the small intestines, due
to differences in effective surface areas and ability to absorb die-
tary Cr [39,42,43]. Similarly, based upon consideration of tissue
physiology and function, the model assumes that absorption of
chromium in the large intestines is negligible. Unabsorbed
chromium is excreted in the feces.3.2.2. Conceptual model for chromium in systemic tissues
Cr(VI) that reaches portal plasma is subject to several compet-
ing processes: (1) reduction to Cr(III) (process 2c in Fig. 2); (2) up-
take into erythrocytes (followed by intracellular reduction,
resulting in an increased erythrocyte:plasma ratio as described in
Section 3.1); and (3) transit to the liver (process R5 in Fig. 2). Inclu-
sion of separate compartments in the model for portal plasma and
erythrocytes (i.e., separate from systemic plasma and erythro-
cytes), provides opportunity for Cr(VI) to come into contact with
erythrocytes prior to reaching the liver. Based on the consistency
of the liver:kidney ratios for total chromium reported for Cr(VI)
and Cr(III) exposures in rats and mice (Fig. 1; discussed in Sec-
tion 3.1), it is expected that essentially all chromium entering
systemic plasma from the hepatic/portal system will have been
reduced to Cr(III). The distribution of Cr(III) to tissues is largelydetermined by its binding to low molecular weight proteins, which
may help to explain how plasma chromium levels remain rela-
tively low despite much higher concentrations in tissues [1,25].
Transferrin, an 80 kDa protein is important for delivery of iron
to tissues, possesses two binding sites, one of which has a high
afﬁnity for Cr(III) (i.e., Cr(III) will displace iron at neutral pH)
[36], and therefore is expected to play an important role in the
delivery of Cr(III) from the GI tract to tissues. Based on the mech-
anism for iron absorption, transferrin-bound chromium is likely ta-
ken up from plasma into a cell vesicle via a receptor-mediated
endocytosis [44]. A reduction in the pH of the intracellular vesicle
triggers the release of chromium from transferrin, where chro-
mium is available to bind to other intracellular proteins, and trans-
ferrin is then recycled back to plasma [45]. A low-molecular weight
protein (MW 1500) that is capable of tightly binding Cr(III) has
been detected in a number of tissues [36,46–48]. The highest con-
centrations of chromium in rodent systemic tissues following
Cr(III) or Cr(VI) exposures are typically found in the liver, kidney,
and bone [1,25,30,32]. Cr(III) is released from tissues and excreted
in the urine bound to low molecular weight protein(s) [36]. Biliary
excretion of chromium is expected to be negligible [17].4. Results
4.1. Toxicokinetic studies in rats and mice
Tissue concentration data for total chromium from the toxicoki-
netic studies in rats and mice are presented in Tables 2 and 3,
respectively. Chromium concentrations increase in a dose-depen-
dent manner in all tissues in both species (statistically signiﬁcant
trends based on Jonckheere’s test, p < 0.001). The highest concen-
trations of chromium were detected in the mouse duodenum, with
a decreasing longitudinal gradient noted for chromium in the small
intestines (duodenum > jejunum > ileum). Consistent with the data
in the published literature [1], the concentration ratios for chro-
mium concentrations in erythrocytes:plasma are above a value of
1 for the three highest treatment groups in rats (20–180 mg Cr/L)
and the two highest treatment groups in mice (60–180 mg Cr/L).
With respect to tissue iron content, chromium exposure resulted
in a statistically signiﬁcant decrease in iron concentration for all
three sections of the small intestines and the liver in both species
at the higher doses (see Appendix A).
4.2. PBPK model
Although a rat PBPK model for chromium has been previously
developed [17], inspection of the model structure, parameteriza-
tion, and predicted behaviors revealed that it would not be easily
modiﬁed to reﬂect the conceptual model described above. For this
reason a new model was developed as described below.
4.2.1. Model structure
The GI model was deﬁned to contain compartments for the oral
cavity, lumped forestomach/glandular stomach, and small intes-
tines. The small intestines was subdivided into compartments for
the duodenum, jejunum, and ileum, so that gradients in pH, Cr(VI)
reduction, and tissue dose can be better characterized. A non-phys-
iologic compartment (i.e., no blood ﬂow, lumen volume, or tissue
volume deﬁned) was included in the model for the large intestines
to coordinate transit times with fecal excretion data. GI lumen vol-
umes were deﬁned based upon the data of McConnell et al. [49] for
lumen contents in both rats and mice. Lumen transit rates (rate R1
in Fig. 2) for chromium and chromium reducing equivalents were
assumed to be the same (i.e., lumen contents were assumed to
transit as a homogenate). Although some temporal variation in
Table 2
Tissue total chromium concentrations (mg/kg) in rats exposed to Cr(VI) in drinking water for 90 days.
Drinking water concentration, mg SDD/L
(dose in mg Cr/kg day)
Oral* Stomach Duodenum Jejunum Ileum Plasma Erythrocyte Liver
0 (0) 0.13 ± 0.16 0.15 ± 0.23 0.04 ± 0.02 0.03 ± 0.01 0.06 ± 0.04 0.014 ± 0.0003 0.015 ± 0.004 0.02 ± 0.01
0.3 (0.015) 0.07 ± 0.07 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.014 ± 0.0003 0.013 ± 0.001 0.01 ± 0.00
4 (0.21) 0.05 ± 0.00 0.07 ± 0.06 0.49 ± 0.14 0.13 ± 0.14 0.04 ± 0.02 0.014 ± 0.0000 0.014 ± 0.004 0.04 ± 0.02
60 (2.9) 1.0 ± 0.35 1.2 ± 0.50 18.2 ± 2.8 5.1 ± 3.7 0.85 ± 0.5 0.15 ± 0.014 0.32 ± 0.031 1.9 ± 0.35
170 (7.2) 2.1 ± 0.30 7.0 ± 2.4 25.7 ± 3.3 7.9 ± 7.7 1.6 ± 1.9 0.21 ± 0.026 0.51 ± 0.14 3.6 ± 0.92
520 (20.5) 5.0 ± 0.70 16.4 ± 5.3 32.2 ± 7.7 5.8 ± 3.0 1.2 ± 0.51 0.31 ± 0.017 0.77 ± 0.08 7.1 ± 1.1
* n = 5; bolded values are signiﬁcantly different from controls (Shirley’s test, p < 0.05).
Table 3
Tissue total chromium concentrations (mg/kg) in mice exposed to Cr(VI) in drinking water for 90 days.
Drinking water concentration,
mg SDD/L (dose in mg Cr/kg day)
Oral* Stomach Duodenum Jejunum Ileum Plasma Erythrocytes Liver
0 (0) 0.25 ± 0.24 0.060 ± 0.019 0.017 ± 0.007 0.046 ± 0.044 0.020 ± 0.009 0.014 ± 0.000 0.014 ± 0.000 0.013 ± 0.003
0.3 (0.024) 0.18 ± 0.10 0.052 ± 0.023 0.056 ± 0.015 0.034 ± 0.021 0.014 ± 0.000 0.042 ± 0.035 0.033 ± 0.043 0.014 ± 0.000
4 (0.32) 0.21 ± 0.21 0.088 ± 0.016 1.5 ± 0.27 0.11 ± 0.052 0.042 ± 0.033 0.016 ± 0.003 0.014 ± 0.000 0.12 ± 0.042
14 (1.1) 0.66 ± 0.34 0.38 ± 0.086 7.3 ± 0.78 0.33 ± 0.29 0.13 ± 0.027 0.16 ± 0.032 0.11 ± 0.029 0.68 ± 0.14
60 (4.6) 3.7 ± 3.1 2.2 ± 0.27 33.5 ± 5.0 4.7 ± 3.3 0.92 ± 1.0 0.36 ± 0.051 0.32 ± 0.049 4.4 ± 0.61
170 (11.6) 4.1 ± 2.6 4.3 ± 0.64 42.4 ± 12.4 21.6 ± 14.8 1.8 ± 1.1 0.72 ± 0.080 1.0 ± 0.16 14.8 ± 3.2
520 (30.9) 7.9 ± 4.4 21.2 ± 1.6 60.9 ± 14.1 13.9 ± 6.9 2.3 ± 0.86 0.78 ± 0.11 1.8 ± 0.2 44.8 ± 11.1
* n = 5; bolded values are signiﬁcantly different from controls (Shirley’s test, p < 0.05).
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pear to be fairly low [49], in part due to the continuous feeding pat-
tern of rodents, and the storage and regulating effect of the
forestomach [42]. Lumen transit rates for each segment of the GI
tract were modeled using the following equation:
Rtransðmg=hÞ ¼ KtransAmt
where, Rtrans = rate of lumen transit (mg/h); Ktrans = transit rate
constant (/h); Amt = amount of chromium or reducing equivalents
(mg).
Cr(VI) reduction was deﬁned to occur in the lumen compart-
ments for the stomach and small intestines (rate R2a in Fig. 2),
as well as within all GI tissues (rate R2b in Fig. 2). The pH depen-
dence of Cr(VI) reduction in GI lumen was modeled using the
following equation, based on data from ex vivo studies of human
gastric ﬂuid [28]:
KRED ¼ KexpðpHÞ
where, KRED = pH-dependent rate constant for Cr(VI) reduction in
GI lumen (L/mg h); K = reduction rate constant (L/mg h) at pH of 0.
The rate of reduction is then calculated as:
RREDðmg=hÞ ¼ ½CrKREDRE
where, RRED = rate of Cr(VI) reduction (mg/h); [Cr] = concentration
of Cr(VI) in GI lumen (mg/L); and RE = amount of reducing equiva-
lent in GI lumen (mg).
Cr(VI) reducing equivalents (RE) in gastrointestinal lumen were
modeled as capacity limited, with regeneration of RE in gastric
contents. The rate for the replenishment of reducing equivalents
was modeled by multiplying the estimated concentration of reduc-
ing equivalents in stomach contents [21] by the rate of stomach lu-
men content inﬂux (i.e., drinking water and food consumption
rates, saliva and gastric ﬂuid production rates). The rodent fore-
stomach and glandular stomach were modeled as a single com-
partment. The reduction of Cr(VI) in gastrointestinal tissues
(stomach, duodenum, jejunum, and ileum) was modeled as a satu-
rable process, assuming classic Michaelis–Menten kinetics. Making
this process saturable was necessary in capturing nonlinear behav-ior for the erythrocyte:plasma ratio (see Section 3.1) as a function
of Cr(VI) dose.
Absorption from the GI lumen into tissues of the GI tract ap-
peared to vary as a function of dose, with lower fractional absorp-
tion at higher dose rates (i.e., above approximately 1 mg Cr/
kg day). Absorption rates (rate R3 in Fig. 2) for Cr(III) and Cr(VI)
were modeled as saturable Michaelis–Menten functions to reﬂect
this behavior. In addition, a longitudinal gradient for the absorp-
tion in the small intestines was permitted in the model for both
Cr(III) and Cr(VI), to allow for differences in absorption per unit
length for the duodenum, jejunum, and ileum using the following
equation:
Absorption rateðmg Cr=hÞ ¼ RALðVMCLÞ=ðKMþ CLÞ
where, RA = relative absorption (relative to duodenum rate, unit-
less); L = section length (cm); VM = maximal rate of absorption
per unit length (mg Cr/h cm); KM = Michaelis–Menten constant
for absorption (mg Cr/L); and CL = chromium lumen concentration
(mg Cr/L).
Although data on the relative absorption between small intes-
tine sections were not located speciﬁcally for Cr(III) or Cr(VI), lon-
gitudinal gradients for absorption in the small intestines have been
reported for other metals (e.g., iron [50]). Absorbed chromium is
released to portal plasma, where it mixes with plasma from the he-
patic artery where it is subject to uptake by the liver or delivery to
systemic plasma.
Systemic Cr(III) was modeled as belonging to two general pools:
(1) a distributional pool (e.g., transferrin-bound Cr(III), but may in-
clude other forms), which describes the distribution of Cr(III) from
the GI tract to tissue via plasma; and (2) a storage/excretion pool
[e.g., Cr(III) bound to low molecular weight protein(s)], which
describes the release of Cr(III) from tissues to plasma, uptake into
kidney, and its ultimate excretion in the urine. Because sufﬁcient
data were not available to adequately parameterize the behavior
of bound forms of Cr(III), some simplifying assumptions were
made in the model: (1) Cr(III) in the distribution pool is available
from plasma to all systemic tissues; and (2) Cr(III) delivered from
plasma to tissues becomes part of the storage/excretion pool,
which upon re-release to plasma is available for uptake by the
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other tissues is assumed to be negligible). No attempts were made
to model the intracellular toxicokinetics of bound Cr(III) forms
[e.g., release from transferrin, binding to low molecular weight
protein(s)]. Instead, chromium in the distribution pool was as-
sumed to enter the storage/excretion pool upon reaching systemic
tissues. For all forms of chromium, distribution between plasma
and systemic tissues was determined by ‘‘transfer efﬁciency’’
terms, which are multiplied by tissue blood ﬂows:
Tissue uptakeðmg Cr=hÞ ¼ TEastCBPastQT
where, TE = transfer efﬁciency (unitless); CBP = concentration of
chromium in blood plasma (mg Cr/L); and QT = tissue blood ﬂow
rate (L/h).
Chromium that has been taken up into enterocytes can re-enter
the GI lumen as cells are sloughed off, which is modeled as follows:
Rsloughðmg=hÞ ¼ KsloughAgit
where, Rslough = rate chromium in GI tissues is released into GI lu-
men (mg/h); Kslough = rate constant for GI tissue cell sloughing (/
h); and Agit = amount of chromium in GI tissue (mg).
The structure of the chromium PBPK model is depicted in Fig. 3,
and the acslX code for the model is provided in Appendix B.
4.2.2. Model parameterization
For both species, physiological parameters (body weight, tissue
volumes, tissue blood ﬂows) were set to study-speciﬁc values
where available; otherwise default values were obtained from
the published literature [51] (Tables 4 and 5). Tissue lengths and
volumes for the small intestines sections were collected in this
study, and are generally consistent with those reported for ratsFig. 3. PBPK model structure. RBC = red blood cells; O = oral mucosa; S = stomach;
D = duodenum; J = jejunum; I = ileum; LI = large intestines; all compartments can
contain Cr(VI), light shaded arrows and compartments depict Cr(III) in the
distribution pool; dark shaded arrows and compartment depict Cr(VI) in the
storage/excretion pool; intermediate shaded compartments (plasma) contain both
Cr(III) pools.by Roth et al. [67]. GI lumen content volumes in rats and mice were
obtained from the published literature [49]. Transit rate for con-
tents of the oral cavity lumen was assumed to be relatively short
(halftime of 3 s). GI transit rates, which apply to the transit of
chromium and chromium reducing equivalents, were estimated
by ﬁtting rates to data for chromium in stomach, small intestines,
large intestines, and/or feces in rats and mice exposed to chro-
mium [25,52,53] (Fig. 4). Transit rate values for both species were
optimized simultaneously, by using an adjustable time scaling fac-
tor for species differences (i.e., optimized mouse transit rates for
each GI segment were estimated to be approximately 3.9 times fas-
ter than corresponding segment rates in rats). By ﬁtting both spe-
cies simultaneously, transit data for the small and large intestines
in the rat could be used to ﬁll in data gaps for the mouse (i.e., lack
of measurements for small and large intestines; Fig. 4B). Transit
rates estimated for the small intestines were apportioned between
the duodenum, jejunum, and ileum according to their relative
lengths as measured in this study (Table 4). Rates for ingestion,
food consumption, saliva production, and gastric ﬂuid production
were set to study-speciﬁc values where available, obtained from
the published literature [42,43,54] (Table 4).
Model parameters for the reduction of Cr(VI) in the GI tract lu-
men, including pH-dependent rate constants and concentrations of
reducing equivalents in stomach contents, are based on ex vivo
data and modeling for rats and mice [21,28]. Model parameters
for the reduction of Cr(VI) in GI tissues were deﬁned as follows.
The rate (V/K) of reduction in GI cells was assumed to be the same
as estimated in rat erythrocytes (71 h1; see below). The value for
Km in GI tissue reduction was adjusted to obtain ﬁts to the eryth-
rocyte:plasma ratio data for rats and mice collected in this study
(calculated from data in Tables 2 and 3).
Model parameters for the reduction of Cr(VI) in systemic tissues
are derived from limited available datasets. Reduction rates in
plasma (0.66 h1) and erythrocytes (71 h1) are estimated from
in vitro rat data from Richelmi and Baldi [38]. Because pH is not ex-
pected to vary within tissues, and because the availability of intra-
cellular reducing equivalent is not expected to be rate limiting, the
reduction value of 71 h1 was applied to all tissues, independent of
pH and concentration. A similar reduction rate constant (approxi-
mately 68 h1) was derived from ﬁts to in vitro data for the disap-
pearance of chromate in mouse liver supernatant [48].
All other model parameters were obtained by adjusting their
values to obtain model predictions that ﬁt available rat and mouse
data sets based upon visual and statistical optimization. Prior to
modeling, tissue time-course concentrations for the key data sets
(Table 1) were converted to added chromium, which was
calculated as: (tissue chromium concentration in exposed ani-
mals)  (tissue chromium concentration in control animals).
Model parameters for Cr(III) tissue uptake and release in rats
were set by ﬁtting the data of NTP [25], MacKenzie et al. [31],
and depuration data of Thomann et al. [30]. Although Thomann
et al. [30] examined oral exposures to Cr(VI), the tissue data from
depuration phase of the study are expected to reﬂect Cr(III) kinet-
ics (i.e., all Cr(VI) has been reduced by that point). The data from
NTP for Cr(III) in rats and mice [25; Fig. 5], are strongly supportive
of reduced absorption at high doses, since initial attempts to use a
linear absorption rate across all doses resulted in a large (approx-
imately 7- to 10-fold) overestimation of tissue concentrations at
the highest doses. For the GI tissues, no data sets are available
for Cr(III) exposures, and therefore model parameter values for
the ﬂux of Cr(III) into and through GI tract tissues were estimated
using the low-dose Cr(VI) data collected for rats in this study
(Table 2). This was done using ex vivo reduction data [21] indicat-
ing that the majority of the chromium ingested is reduced to Cr(III)
in the GI lumen at low doses. Overall, the model provides a
reasonable description of the Cr(III) data sets for rats (Fig. 5A–E;
Table 4
GI model parameters.
Group Description Symbol Units Rat
value
Mouse
value
Source
Tissue volumes Duodenum vdc Unitless
(fraction of
body weight)
0.0019 0.012 Measured (this study)
Ileum vic 0.001 0.0063
Jejunum vjc 0.012 0.021
Oral cavity voc 0.0003 0.00076
Stomach vsc 0.0028 0.0053
Blood ﬂows
(rate R5 in Fig. 2)
Duodenum qdc Unitless
(fraction of
portal ﬂow or
cardiac output)
0.11 0.28 Fraction of cardiac (oral cavity) or portal (all others)
blood ﬂows were assumed to be proportionate to
tissue volume fractions of body weight
Ileum qic 0.06 0.14
Jejunum qjc 0.67 0.46
Oral cavity qoc 0.0003 0.00076
Stomach qsc 0.16 0.12
Transit rate
R1 in Fig. 2)
Oral to stomach klos hr1 830 830 Values for oral cavity transit assumed to be rapid
(approximately 3 seconds). Lumen transit rates for
stomach, small intestines, and large intestines,
were optimized by adjusting rates to
simultaneously ﬁt GI lumen and fecal concentration
data [25,52,53]. Rate constants for small intestines
sections apportioned by length measurements from
this study
Stomach to
duodenum
klsd 2.4 9.4
Duodenum to
jejunum
kldj 3.6 4
Jejunum to ileum klji 0.3 2
Ileum to large Int. klil 3.2 4.1
Large Int. to feces kfx 0.059 0.23
Lumen content rates
(factor for rate
R2a in Fig. 2)
Food intake rfood L/h kg 0.0021 0.0054 Study-speciﬁc data used where available. Default
values for food and water [54]. Saliva production
rate scaled from the published literature [72].
Gastric ﬂuid rates reﬂect the midpoint of ranges
reported for basal rates [19]
Water intake rdrink 0.0058a 0.0089b
Saliva production rsal 0.0067 0.0067
Gastric ﬂuid
production
rgif 0.0022 0.0035
Lumen volumes Stomach lumen
volume
vslc Fraction body
weight
0.011 0.014 Lumen content volumes were obtained from
McConnell et al. [49]
Duodenum lumen
volume
vdlc 0.0016 0.0078
Jejunum lumen
volume
vjlc 0.02 0.016
Ileum lumen
volume
vilc 0.0018 0.0077
Lumen Stomach pH phs Unitless 4.5 4.5 Stomach pH values for both species are based on
ex vivo measurements [21]. pH values for small
intestines lumen sections were based on data from
McConnell et al. [49]
pH (factor for rate
R2a in Fig. 2)
Duodenum pH phd 5 4.9
Jejunum pH phj 5.1 4.8
Ileum pH phi 5.9 4.8
Reduction (rates R2a
and R2b in Fig. 2)
Reducing
equivalents in
gastric ﬂuid
cre0 mg/L 15.7 16.6 Lumen reduction values based on ex vivo rat and
mouse data from Proctor et al. [21]. pH dependence
for reduction is based on a relationship observed
using human [28]. Tissue reduction rate (V/
K = 71 h1) based on reduction rates obtained from
ﬁts to data for rat erythrocytes [38]. The Km values
for Cr(VI) reduction in GI tissue were adjusted to ﬁt
the RBC:plasma ratio data collected in this study
pH-Dep 2nd order
rate constant, GI
lumen
kredgifc L/mg h 27 18
Michaelis–Menten
constant, GI tissue
kmredgit mg/L 5.00E-07 3.90E-06
V:K ratio for
reduction, GI tissue
vkredgit hr1 71 71
Maximal rate
reduction, GI tissue
vmaxredgit mg L/h Calculated Calculated
GI absorption and Oral uptake of klo3 hr1 0 0 Oral uptake of Cr(III) was assumed to be negligible.
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Table 4 (continued)
Group Description Symbol Units Rat
value
Mouse
value
Source
sloughing (rate R3
and R6 in Fig. 2)
Cr(III) Oral uptake rates for Cr(VI) in rats and mice were
manually adjusted to provide ﬁts to tissue data
collected in this study. Vmax and Km values for Cr(III)
absorption into SI tissue were optimized to ﬁt data
from NTP [25]. Km values for Cr(VI) absorption into
SI tissue were adjusted to ﬁt data from NTP [1] and
this study
Oral uptake of
Cr(VI)
klo6 hr1 4.00E-08 2.10E-08 Vmax values for Cr(VI) absorption were optimized to
ﬁt each data set. Km and Vmax for Cr(III) and Cr(VI)
absorption into stomach tissue were manually
adjusted to ﬁt data from NTP [1,25] and this study.
Relative absorption in the small intestines
(duodenum deﬁned as 1) for Cr(III) and Cr(VI were
optimized to ﬁt the data collected in this study.
Values for the rate of cell sloughing for the upper GI
(oral cavity, stomach) and small intestines are
based on cell turnover times of approximately 5
and 2 days, respectively [66], which were adopted
for both species. SI section lengths were measured
in this study for both rats and mice
Max rate Cr(III)
abs., stomach
vmabs3s mg/h 1.00E-05 2.00E-05
Max rate Cr(VI)
abs., stomach
vmabs6s mg/h 8E-04c 4E-04d
MM constant Cr(III)
abs., stomach
kmabs3s mg/L 1000 120
MM constant Cr(VI)
abs., stomach
kmabs6s mg/L 150e 100
Max rate Cr(III) abs,
per cm SI
vmabs3 mg/cm h 9.00E-05 2.6E-05
Max rate Cr(VI) abs,
per cm SI
vmabs6 mg/cm h 1.0E-04f 6.2E-05g
MM constant Cr(III)
absorption, SI
kmabs3 mg/L 300 50
MM constant Cr(VI)
absorption, SI
kmabs6 mg/L 7.3h 6.2
Rel uptake by
duodenum of Cr(III)
rad3 Unitless 1 1
Rel uptake by
duodenum of Cr(VI)
rad6 Unitless 1 1
Rel uptake by
jejunum of Cr(III)
raj3 Unitless 0.26 0.34
Rel uptake by
jejunum of Cr(VI)
raj6 Unitless 0.14 0.18
Rel uptake by ileum
of Cr(III)
rai3 Unitless 0.048 0.066
Rel uptake by ileum
of Cr(VI)
rai6 Unitless 0.024 0.018
Oral/stomach cell
sloughing
kslough1 hr1 0.012 0.012
SI cell sloughing kslough2 hr1 0.029 0.029
Duodenum length dl cm 5.6 9.2
Jejunum length jl cm 68.3 18.9
Ileum length il cm 6.4 9
Blood: tissue
transfer (rate
R4 in Fig. 2)
T–Cr(III): GI tissue
to plasma
kout3 Unitless 0.0016 0.00074 Values for the rate constant for the release of Cr(III)
and Cr(VI) into blood (distribution pool) optimized
to ﬁt data from this study for both rats and mice.
Values for the release of Cr(III) into blood (excretion
pool) were manually adjusted to ﬁt data from NTP
[25]
Cr(VI): GI tissue to
plasma
kout6 0.0017 0.0045
C–Cr(III): GI tissue
to plasma
koutccrgi 0i 0j
a For NTP [1] rdrink = 0.002 L/h kg; for this study rdrink = 0.0061 L/h kg; for NTP [25] rdrink = 0.0042 L/h kg.
b For NTP [25] rdrink = 0.0079 L/h kg; for NTP [1] rdrink = 0.0027 L/h kg; for NTP [29] rdrink = 0.015 L/h kg.
c For NTP [1] vmabs6s = 0.02 mg/L.
d For NTP [1] vmabs6s = 0.005 mg/h.
e For NTP [1] kmabs6s = 1000 mg/L.
f For Thomann et al. [30] vmabs6 = 0.00011; for this study vmabs6 = 0.000054; for NTP [1] and MacKenzie et al. [31] vmabs6 = 0.00019.
g For NTP [1] vmabs6 = 9.4E-05 mg/cm h; for Kargacin et al. [32] vmabs6 = 5.2E-05 mg/cm h; for NTP [29] a geometric mean of 6.7E-05 mg/cm h was used.
h For NTP [1] kmabs6 = 3.5 mg/L.
i For NTP [25] koutccrgi = 0.003.
j For NTP [25] koutccrgi = 0.0001.
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Table 5
Systemic model parameters.
Group Description Symbol Units Rat value Mouse
value
Source
Tissue volumes Bone vbc Unitless
(fraction of body weight)
0.073 0.107 Tissue volumes were obtained from Brown
et al. [51]
Blood vblc 0.074 0.049
Fraction portal fpt 0.153 0.141
Hematocrit hct 0.45 0.45
Kidney vkc 0.007 0.017
Liver vlc 0.034 0.055
Other tissues votc Calculated Calculated
Tissue blood
ﬂows
Bone qbc Unitless
(fraction of cardiac output)
0.12 0.12 Tissue blood ﬂows were obtained from
Brown et al. [51]
Kidney qkc 0.141 0.091
Liver (excluding portal) qlc 0.03 0.02
Other tissues qotc Calculated Calculated
Blood tissue
transfer
coefﬁcients
Cr(VI): plasma to tissue kin6 Unitless 1.2 8 Rate constants for the uptake of Cr(VI) from
plasma to tissues were optimized to obtain
ﬁts to liver tissue data collected in this
study. Rate constants for the uptake of
distribution pool Cr(III) from plasma to
systemic tissues were optimized to obtain
ﬁts to data sets for Cr(III) [25,31]. Rate
constants for the uptake of Cr(VI) from
plasma to erythrocytes were optimized to
obtain ﬁts to erythrocyte:plasma ratio data
collected in this study. Rate constants for
the release of storage pool Cr(III) from
tissues to plasma were optimized from ﬁts
to multiple data sets [1,25,30–32]
C–Cr(III)a: plasma to kidney kinccr Unitless 0.09 0.03
T–Cr(III) a: plasma to bone kintcrb Unitless 0.059
b 0.25
T–Cr(III): plasma to kidney kintcrk Unitless 0.03 0.01
T–Cr(III): plasma to liver kintcrl Unitless 0.0093 0.081
T–Cr(III): plasma to other kintcrot Unitless 0.018 0.03
C–Cr(III): bone to plasma koutccrb Unitless 3.40E-04 5.70E-06
C–Cr(III): liver to plasma koutccrl Unitless 4.50E-04 4.00E-04
C–Cr(III): other to plasma koutccrot Unitless 9.00E-04 2.00E-04
Cr(VI): plasma to erythrocyte krbcin6 L/h 0.0066 0.008
T–Cr(III): plasma to erythrocyte krbcin3 L/h 1.20E-05 1.80E-05
C–Cr(III): erythrocyte to plasma krbcout3 L/h 1.00E-05 3.00E-06
Reduction
in tissues
Cr(VI) reduction in tissues kred /h 71 71 For rats, rates for reduction in erythrocytes
and plasma are based ﬁts to the data of
Richelmi and Baldi [38]. The intracellular
reduction rate estimated for erythrocytes
was adopted for all tissue compartments.
All rat values for systemic Cr reduction
were adopted for the mouse
Cr(VI) reduction in plasma kredbp 0.66 0.66
Cr(VI) reduction in erythrocytes kredrc 71 71
Excretion Urinary excretion rate kurcc /h 5.4E-05c 4E-05d Urinary excretion rates were optimized by
adjusting model ﬁts to urine and kidney
data from multiple data sets [1,25,30]
General Body weight wbody kg 0.3
e 0.03f Study-speciﬁc values were used where
available, otherwise default values were
used [51]
Cardiac output qcc L/h 14 14
a C–Cr(III) and T–Cr(III) refer to plasma Cr in the excretion and distribution pools, respectively.
b For MacKenzie et al. [31] Cr(III) data and Kargacin et al. [32] data, kintcrb = 0.015.
c For NTP [25] kurcc = 0.00012 h1.
d For NTP [25] kurcc = 0.0001 h1.
e For NTP [25] wbody = 0.36 kg; for Thomann et al. [30] wbody = 0.288 kg; for this study wbody = 0.15 kg; for NTP [1] wbody = 0.4 kg; for NTP [29] wbody = 0.17 kg.
f For NTP [25] wbody = 0.04 kg; for this study wbody = 0.023 kg; for NTP [1] wbody = 0.045 kg.
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Cr(III) absorbed in the NTP studies is very low and decreases in a
dose-dependent manner, ranging from approximately 0.001 at
the low dose to 0.0002 at the high dose. This dose-dependency is
conceptually consistent with observations in humans for which
an inverse relationship between absorption fraction and dietary in-
take has been reported [55]. Similarly, changes in chromium
absorption to offset changes in urinary chromium loss have been
reported in rats [52], suggesting that adaption of toxicokinetic
processes due to chromium status is plausible. Model ﬁts to chro-
mium picolinate data [25] required adjustment of two model
parameters to ﬁt the urinary excretion data, including increasing
the amount of chromium absorbed directly to the excretion pool
(koutccrgi = 0.005) and urinary excretion (kurcc = 0.00011). These
adjustments are interpreted as the absorption and rapid excretion
of additional chromium as picolinate (i.e., in addition to chromiumbound to low molecular weight protein(s) following tissue absorp-
tion and excretion).
While holding the Cr(III) model parameters constant, rat model
parameters for the ﬂux of Cr(VI) into and through GI tract tissues
were set by ﬁtting the high-dose data collected in this study
(Table 7). The stomach concentration values of the NTP [1] data
set were found to be considerably higher than those collected here,
requiring a higher rate for uptake from the stomach lumen
(vmabs6s = 0.02 mg/h). An explanation for this disparity is not
readily apparent. Systemic distribution parameter values in rat
model were set by ﬁtting the data from MacKenzie et al. [31]
(Table 6), NTP [1] (Fig. 6), Thomann et al. [30] (Fig. 7), and Kargacin
et al. [32] (Fig. 8). Overall, the model provides a good description of
the Cr data sets for rats, with model predictions for tissue Cr falling
within a factor of 3 or less of the measured values for approxi-
mately 90% of the data points. However, the bone concentration
Fig. 4. Predictions and data for gastrointestinal transit [25,52,53]. (A) Data and predictions for rats. (B) Data and predictions for mice. Solid lines = model predictions,
diamonds = stomach data, squares = small intestines data, triangles = large intestines data, circles = fecal data. Data points indicate the mean value for 3–10 animals.
Fig. 5. Model ﬁt to tissue data (mean of 3–6 animals per data point) for rats exposed to 2000, 10,000, or 50,000 ppm chromium picolinate in feed (10.7–286 mg Cr(III)/
kg day) for 4, 11, 180 days (followed by 2 days in metabolism cages) [25]: (A) Erythrocytes, (B) Liver, (C) Urine, (D) Plasma, (E) Kidney. 2000 ppm (squares = measured, light
dashed line = predicted), 10,000 ppm (diamonds = measured, heavy dashed line = predicted), 50,000 ppm (squares = measured, solid line = predicted). Model predictions for
the 2-day washout period are only depicted for the last time point. Both axes are log-scale. Data points indicate the mean value for 3–6 animals.
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[31] and Kargacin et al. [32] data, bone concentrations were lower
than reported in Thomann et al. [30], which required a lower value
for transfer from plasma to bone (kintcrb = 0.015). However, pref-
erence was given to the bone data of Thomann et al. [30], due to
their robustness (i.e., inclusion of depuration data and a wide rangeof time points; providing mass-balance data for all tissues). In
addition, although the model depicts the behavior (i.e., slope of
the depuration curve) that is consistent with observations for the
blood data of Thomann et al. [30], it consistently underestimates
the magnitude (Fig. 7B). Because the added chromium concentra-
tions used for the Thomann et al. [30] study were calculated using
Table 6
Model predictions for added Cr in rats exposed to 25 mg Cr/L as Cr(III) or 0.45–25 mg Cr/L as Cr(VI) in drinking water for 1 year [31] (measured data reﬂect mean ± SD for added
Cr; n = 16–20).
Cr(III) exposure Cr(VI) exposure
25 ppm 0.45 ppm 2.2 ppm 4.5 ppm 7.7 ppm 11.2 ppm 25 ppm
Tissue Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred.
Kidney 1.6 ± 0.8 1.2 0.07 ± 0.07 0.11 0.12 ± 0.13 0.53 0.51 ± 0.42 1.1 2.6 ± 0.2 1.9 3.9 ± 1.0 2.8 11.9 ± 3.4 6.5
Liver 0.38 ± 0.09 0.26 BG – 0.06 ± 0.07 0.10 0.25 ± 0.14 0.31 0.56 ± 0.14 0.59 1.4 ± 0.3 0.90 5.6 ± 1.5 2.2
Bone 0.36 ± 0.4 0.45 0.02 ± 0.1 0.13 0.63 ± 0.14 0.62 1.5 ± 0.7 1.2 3.5 ± 1.7 2.0 4.2 ± 1.5 3.0 5.6 ± 2.3 6.7
BG = concentration indistinguishable from background levels.
Table 7
Model predictions for added Cr in rats exposed to 0.3–520 mg SDD/L in drinking water (0.21–20.5 mg Cr(VI)/kg day) for 90 days (measured data reﬂect the mean ± SD for added
Cr; n = 5).
0.21 mg/kg day⁄ 2.9 mg/kg day 7.2 mg/kg day 20.5 mg/kg day
Tissue Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred.
Oral cavity 0.02 ± 0.004 0.050 1.0 ± 0.4 0.71 2.1 ± 0.3 1.9 5.0 ± 0.7 5.5
Stomach 0.04 ± 0.06 0.099 1.1 ± 0.5 1.5 6.9 ± 2.4 4.3 16.4 ± 5.3 14
Duodenum 0.44 ± 0.14 0.98 18.2 ± 2.8 13 25.7 ± 3.3 25 32.2 ± 7.7 32
Jejunum 0.10 ± 0.14 0.12 5.1 ± 3.7 1.8 7.9 ± 7.7 7.2 5.8 ± 3.0 10
Ileum 0.06 ± 0.02 0.025 0.78 ± 0.50 0.36 1.5 ± 1.9 1.5 1.1 ± 0.5 2.0
Plasma 0.014 ± 0 0.0043 0.14 ± 0.01 0.061 0.20 ± 0.03 0.18 0.30 ± 0.02 0.27
Erythrocytes 0.015 ± 0.0004 0.0028 0.31 ± 0.03 0.92 0.50 ± 0.14 0.42 0.76 ± 0.08 0.74
Liver 0.02 ± 0.02 0.047 1.9 ± 0.4 0.96 3.5 ± 0.9 3.6 7.1 ± 1.1 6.1
⁄Tissue concentrations collected at the lowest dose are very close to background levels, and therefore the reported values for added Cr are more uncertain than those collected
at higher doses.
Fig. 6. Model ﬁt to tissue data for rats exposed to 5, 20, 60, or 180 mg Cr(VI)/L in drinking water for 4, 11, 180, or 369 days (0.25–7.4 mg Cr(VI)/kg day) followed by 2 days in
metabolism cages [1]: (A) Erythrocytes, (B) Liver, (C) Stomach, (D) Plasma, (E) Kidney, (F) Urine. 5 mg Cr/L (circles = measured, dash dot line = predicted), 20 mg Cr/L
(triangle = measured, light dashed line = predicted), 60 mg Cr/L (diamond = measured, heavy dashed line = predicted), 180 mg Cr/L (square = measured, solid line = predicted).
Model predictions for the 2-day washout period are only depicted for the last time point. Both axes are log-scale. Data points indicate the mean value for 3–6 animals.
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tion for this difference is that the animals in Thomann et al. [30]
had a higher background concentration of chromium in blood
than was estimated. Use of a value for blood volume (needed to
calculate a concentration from a percentage) that is different from
the one reported by the study authors serves as another possible
explanation. Consistent with expectations of higher membrane
permeability for Cr(VI), the predicted time-weighted average for
the fraction of chromium absorbed in the Cr(VI) rat studies is high-er than that noted above for Cr(III), ranging from approximately
0.002 to 0.005 of ingested chromium.
Model parameters for Cr(III) tissue uptake and release in mice
were set using the data of NTP [25], and relied upon rat model
parameter values where data are lacking. Urine data were not
available for mice in this study [25] and therefore for the sake of
consistency with treatment of the rat data from this study, a higher
release from GI tissues to the storage excretion pool and a higher
urinary excretion rate were adopted for the chromium picolinate
Fig. 7. Model ﬁt to tissue data for rats exposed to 100 mg Cr(VI)/L in drinking water for 42 days followed by 140 days of depuration [30]: (A) Liver, (B) Blood, (C) Bone, (D)
Carcass, (E) Kidney. X = measured, solid line = predicted. Y-axis is log-scale. Data points indicate data for individual animals.
Fig. 8. Model ﬁt to tissue data for rats exposed to 130 mg Cr/L in drinking water for 8 weeks [32]: (A) Liver, (B) Kidney, (C) Other, (D) Blood, (E) Bone. X = measured, solid
line = predicted. Y-axis is log-scale. Data points indicate the mean value for 4–15 animals.
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exposures, and therefore model parameter values for the ﬂux of
Cr(III) into and through GI tract tissues were set using the low-dose
data for mice collected in this study for Cr(VI) (Table 3) because the
majority of lumen chromium is expected to be Cr(III) at low doses.
The model provides a reasonable description of the Cr(III) data set
for mice (Fig. 9). The predicted time-weighted average for the frac-
tion of Cr(III) absorbed in the NTP studies is again very low and de-
creases in a dose-dependent manner, ranging from approximately
0.0002 at the low dose to approximately 0.00002 at the high dose.
While holding the Cr(III) model parameters constant, mouse
model parameters for the ﬂux of Cr(VI) into and through mouse
GI tract tissues were set by ﬁtting model predictions to high-dose
data collected in this study (Table 8). Again, the stomach tissue
concentration values of the NTP [1] data set in mice were consid-
erably higher than those collected here, requiring a higher ratefor uptake from the stomach lumen (vmabs6s = 0.005). An expla-
nation for this disparity is not readily apparent, but it is possibly
related to differences in water intake since NTP study animals
drank only about one-half of the volume of drinking water, in all
dose groups including controls, as compared to the Thompson
et al. [19,20] animals. Systemic model parameters for Cr(VI) distri-
bution were then set using the data of NTP [1] (Fig. 10) and Karg-
acin et al. [32] (Fig. 11). Overall, the model provides a good
description of the Cr data sets for mice, with model predictions
falling within a factor of 3 or less of the measured values for
approximately 80% of available data points. However, there was a
tendency for the model to overestimate plasma concentrations at
the two highest doses for the NTP [1] data set (Fig. 10D). The data
for plasma collected at the highest two doses exhibit an interesting
behavior in that they appear to decrease with time (i.e., levels de-
tected on days 180 and 360 of exposure are lower than reported at
Fig. 9. Model ﬁt to tissue data for mice exposed to 2000, 10,000, or 50,000 ppm chromium picolinate in feed (28.6–728 mg Cr(III)/kg day) for 4, 11, 180 days (followed by
2 days in metabolism cages) [25]: (A) Erythrocytes, (B) Liver, (C) Stomach, (D) Plasma, (E) Kidney. 2000 ppm (triangles = measured, light dashed line = predicted), 10,000 ppm
(diamonds = measured, heavy dashed line = predicted), 50,000 ppm (squares = measured, solid line = predicted). Model predictions for the 2-day washout period are only
depicted for the last time point. Both axes are log-scale. Data points indicate the mean value for 3–6 animals.
Table 8
Model predictions for added Cr in mice exposed to 0.3–520 mg SDD/L in drinking water (0.024–30.9 mg Cr(VI)/kg-day) for 90 days (measured data reﬂect the mean ± SD for
added Cr; n = 5).
0.024 mg/kg day⁄ 0.32 mg/kg day⁄ 1.1 mg/kg day 4.6 mg/kg day 11.6 mg/kg day 30.9 mg/kg day
Tissue Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred. Meas. Pred.
Oral cavity BG – BG – 0.41 ± 0.34 0.29 3.5 ± 3.1 1.2 3.8 ± 2.6 3.3 7.7 ± 4.4 9.3
Stomach BG – 0.028 ± 0.016 0.22 0.32 ± 0.09 0.77 2.2 ± 0.3 3.2 4.3 ± 0.6 7.9 21.1 ± 1.6 20
Duodenum 0.039 ± 0.015 0.21 1.5 ± 0.3 2.7 7.2 ± 0.8 8.6 33.5 ± 5.0 27 42.4 ± 12.4 42 60.9 ± 14.1 54
Jejunum BG – 0.068 ± 0.052 0.34 0.28 ± 0.29 1.1 4.7 ± 3.3 4.5 21.5 ± 14.8 9.1 13.8 ± 6.9 14
Ileum BG – 0.021 ± 0.033 0.051 0.11 ± 0.03 0.18 0.90 ± 1.0 0.73 1.8 ± 1.1 1.6 2.3 ± 0.9 2.5
Plasma 0.028 ± 0.035 0.0013 0.0014 ± 0.0032 0.011 0.15 ± 0.03 0.050 0.34 ± 0.05 0.19 0.71 ± 0.08 0.60 0.77 ± 0.11 1.1
Erythrocytes 0.019 ± 0.043 0.0008 BG – 0.094 ± 0.030 0.033 0.31 ± 0.05 0.11 1.0 ± 0.2 1.1 1.7 ± 0.2 2.4
Liver 0.0014 ± 0 0.026 0.11 ± 0.04 0.34 0.66 ± 0.14 1.1 4.4 ± 0.6 3.7 14.8 ± 3.2 17 44.7 ± 11.1 33
BG = concentrations equivalent to background.
⁄Tissue concentrations collected at the lowest two doses are very close to background levels, and therefore the reported values for added Cr are more uncertain than those
collected at higher doses.
Fig. 10. Model ﬁt to tissue data for mice exposed to 5, 20, 60, or 180 mg Cr/L in drinking water for 4, 11, 180, or 369 days (0.40–10.4 mg Cr(VI)/kg day) followed by 2 days in
metabolism cages [1]: (A) Erythrocytes, (B) Liver, (C) Stomach, (D) Plasma, (E) Kidney, (F) Urine. 15 mg Cr/L (circles = measured, dash dot line = predicted), 20 mg Cr/L
(triangle = measured, light dashed line = predicted), 60 mg Cr/L (diamond = measured, heavy dashed line = predicted), 180 mg/L (square = measured, solid line = predicted).
Model predictions for the 2-day washout period are only depicted for the last time point. Both axes are log-scale. Data points indicate the mean value for 3–6 animals.
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Fig. 11. Model ﬁt to tissue data for mice exposed to 130 mg Cr/L in drinking water for 8 weeks [32]: (A) Liver, (B) Kidney, (C) Other, (D) Blood, (E) Bone. X = measured, solid
line = predicted. Y-axis is log-scale. Data points indicate the mean value for 1–50 animals.
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gesting that the plasma toxicokinetics of chromiummay be altered
during the course of high-dose Cr(VI) exposure. The predicted
time-weighted average for the fraction of chromium absorbed in
the Cr(VI) mouse studies is higher than noted above for Cr(III),
ranging from approximately 0.002 to 0.008 of ingested chromium.
Model predictions for systemic tissue chromium concentrations
were validated against the 21-day exposure data for rats and mice
[29]. In rats, the model provides predictions for chromium that are
consistent with concentrations measured in the blood, bone, and
kidney (Table 9). In mice, the model provides predictions for chro-
mium that are consistent with concentrations measured in the
blood, but overestimates the concentrations in kidney at high
doses of Cr(VI) (Table 9). A comparison of the underlying data for
kidney concentration data for mice in the 21-day and 2-year stud-
ies of NTP reveal some clear differences between these two data
sets. For example, kidney levels of added chromium in mice from
the 21-day study exposed to 300 mg Cr/L for 21 days were lower
(3.5 mg/kg) [29] than those detected in the 2-year study for mice
exposed to 60 mg Cr/L for 13 days (4.1 mg/kg) [1], a difference that
cannot be reconciled with a PBPK model using a single set of
parameter values. One possible explanation for this disparity in-
cludes the potential impact of hydration status on chromium clear-
ance from the kidney because drinking water consumption rates in
the 2-year study by NTP (i.e., the data set used to estimate urinary
excretion rates for mice [1]) were much lower than those reportedTable 9
Model ﬁt to validation data for rats and mice exposed to 2.9, 8.6, 28.7, 86.2, 287, or 862 mg
data reﬂect the mean ± SD for added Cr; n = 3).
0.11 mg/kg day 0.36 mg/kg day 1.2 mg/kg day
Tissue Meas. Pred. Meas. Pred. Meas.
Rats
Blood 0.027 ± 0.057 0.0011 0.005 ± 0.03 0.0037 0.029 ± 0.019
Kidney 0.11 ± 0.12 0.063 0.31 ± 0.11 0.21 1.4 ± 0.4
Bone 0.05 ± 0.4 0.037 BG – 0.57 ± 0.49
0.40 mg/kg day 1.4 mg/kg day 3.2 mg/kg day
Tissue Meas. Pred. Meas. Pred. Meas. Pre
Mice
Blood BG – 0.001 ± 0.05 0.025 0.035 ± 0.10 0.0
Kidney 0.14 ± 0.09 0.12 0.25 ± 0.028 0.39 0.58 ± 0.15 0.7
BG = concentrations equivalent to background.in the 21-day study by NTP [1]. Use of 2-fold higher urinary excre-
tion rate (i.e., assuming renal clearance is dependent upon hydra-
tion) results in model predictions (not shown) that are much
more consistent with the high-dose kidney data of NTP [29].
Results of the sensitivity analysis are dependent upon the inter-
nal dose measure (Table 10). Internal dose measures that may be
useful for human health risk assessment of SI tumors include the
ﬂux of Cr(VI) leaving the stomach lumen (normalized to total SI tis-
sue weight) and the ﬂux of Cr(VI) taken up by SI tissue sections
(also normalized to SI tissue section weight). Internal dose mea-
sures of potential interest for systemic tissues include the fraction
of Cr absorbed, liver:kidney ratio (as discussed in Section 3.1), and
erythrocyte:plasma ratio (also discussed in Section 3.1). For the
ﬂux of Cr(VI) leaving the stomach lumen, model parameters for
stomach lumen pH, SI section volumes, and stomach lumen transit
rate were identiﬁed as the most sensitive. For the ﬂux of Cr(VI)
taken up by SI tissue sections, model parameters for section length,
section volume, relative absorption, and lumen pH were the most
sensitive. Model parameters for absorption rate, lumen reducing
equivalents, blood ﬂow, and GI tissue reduction were the most
sensitive contributors to model predictions for fraction of Cr ab-
sorbed. Urinary excretion, liver-plasma transfer, hematocrit and
cardiac output were the most sensitive contributors to model pre-
dictions of liver:kidney ratio. For erythrocyte:plasma ratio, tissue-
plasma transfer terms, Cr(VI) reduction in tissues, and tissue Cr(VI)
reduction rate were the most sensitive.SDD/L in drinking water for 21 days followed by 2 days washout period [1] (measured
3.5 mg/kg day 11.0 mg/kg day 30.0 mg/kg day
Pred. Meas. Pred. Meas. Pred. Meas. Pred.
0.027 0.21 ± 0.05 0.099 0.39 ± 0.01 0.41 0.53 ± 0.007 0.53
0.75 4.2 ± 1.5 2.3 6.2 ± 0.8 7.8 9.1 ± 0.01 9.8
0.38 1.4 ± 0.5 1.1 2.2 ± 0.4 3.3 3.2 ± 0.7 4.1
12.9 mg/kg day 23.8 mg/kg day
d. Meas. Pred. Meas. Pred. Meas. Pred.
48 0.16 ± 0.09 0.55 0.42 ± 0.08 0.91 0.73 ± 0.02 1.3
8 1.3 ± 0.3 6.8 2.2 ± 0.07 10.8 3.5 ± 0.07 14
Table 10
Sensitivity analysis.⁄
Dose measure Units Rat model Mouse model
Cr(VI) ﬂux from stomach lumen per kg SI tissue mg/kg day Stomach lumen pH (phs: 5.9%) Volume jejunum (vjc: 2.6%)
Volume jejunum (vjc: 3.9%) Volume duodenum (vdc: 1.5%)
Stomach lumen transit (klsd: 2.6%) Stomach lumen pH (phs: 0.9%)
Lumen reducing equivalents (cre0: 2.1%) Volume ileum (vdc: 0.8%)
Lumen reduction rate (kredgifc: 1.3%) Stomach lumen transit (klsd: 0.4%)
Cr(VI) ﬂux into duodenum per kg tissue mg/kg day Length duodenum (ld: 5.0%) Length duodenum (ld: 4.9%)
SI Absorption rate (vmabs6: 5.0%) SI Absorption rate (vmabs6: 4.9%)
Volume duodenum (vdc: 4.8%) Volume duodenum (vdc: 4.8%)
pH duodenum lumen (phd: 1.4%) SI absorption km (kmabs6: 2.6%)
Lumen reducing equivalents (cre0: 1.1%) pH duodenum lumen (phd: 2.3%)
Cr(VI) ﬂux into jejunum per kg tissue mg/kg day Lumen reducing equivalents (cre0: 9.3%) Length jejunum (lj: 4.9%)
Length jejunum (lj: 4.9%) Relative absorption jejunum (raj6: 4.9%)
Relative absorption jejunum (raj6: 4.9%) Volume jejunum (vjc: 4.8%)
Rate salivation (rsal: 4.8%) SI absorption rate (vmabs6: 4.8%)
Volume jejunum (vjc: 4.8%) pH jejunum lumen (phj: 4.1%)
Cr(VI) ﬂux into ileum per kg tissue mg/kg day Lumen reducing equivalents (cre0: 10.4%) Length ileum (li: 5.0%)
Rate salivation (rsal: 5.4%) Relative absorption ileum (rai6: 5.0%)
Length ileum (li: 5.0%) Volume ileum (vic: 4.8%)
Relative absorption ileum (rai6: 5.0%) SI absorption rate (vmabs6: 4.7%)
Volume ileum (vic: 4.8%) pH jejunum lumen (phj: 4.0%)
Fraction absorbed Unitless Lumen reducing equivalents (cre0: 4.6%) SI Absorption rate (vmabs6: 8.6%)
SI absorption rate (vmabs6: 4.0%) Length duodenum (ld: 8.1%)
Portal system blood ﬂow (qptc: 3.9%) GI tissue reduction (vkredgit: 4.9%)
Cardiac output (qcc: 3.9%) GI tissue reduction km (kmredgit: 4.8%)
SI sloughing rate (kslough2: 3.7%) SI absorption km (kmabs6: 4.7%)
Liver:kidney tissue concentration ratio Unitless Urinary excretion (kurcc: 4.9%) Urinary excretion (kurcc: 4.8%)
Hematocrit (hct: 4.7%) Transfer liver to plasma (koutccrl: 4.6%)
Transfer liver to plasma (koutccrl: 4.0%) Cardiac output (qcc: 4.1%)
Cardiac output (qcc: 3.3%) Hematocrit (hct: 3.6%)
Transfer plasma to tissue (kin6: 2.3%) Portal blood ﬂow (qptc: 3.0%)
RBC:plasma concentration ratio Unitless Transfer erythrocyte to plasma (krbcout3: 4.3%) GI tissue reduction rate (vkredgit: 4.9%)
Transfer plasma to erythrocyte (krbcin6: 3.9%) Km for GI tissue reduction (kmredgit: 4.9%)
Volume blood (vblc: 3.8%) Transfer erythrocyte to plasma (krbcout3: 4.8%)
Portal blood volume (fpt: 3.7%) Kidney blood ﬂow (qkc: 4.7%)
Tissue reduction rate (kred: 3.2%) Transfer plasma to kidney (kinccr: 4.7%)
⁄Absolute % change in dose measure following 5 mg Cr(VI)/kg day when parameter value is increased by 5%. Top 5 model parameters shown for each dose measure.
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Ninety-day drinking water studies [19,20] were conducted in
mice and rats to obtain chromium tissue data in the target tissues(A)
Fig. 12. Model predictions for erythrocyte:plasma ratios in rats (A) and micefor tumorigenicity (oral cavity, small intestines), and to supple-
ment the systemic tissue time-course data collected by NTP
[1,25] for the purpose of developing a PBPK model for chromium
in rats and mice. With respect to assessing tumors in the small(B)
(B) as a function of Cr(VI) dose (calculated from data in Tables 2 and 3).
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response concordance and speciﬁcity: (1) tissue concentrations
are higher in the responsive species (mouse) than in the non-
responsive species (rat); and (2) a longitudinal gradient for tissue
concentrations within mouse small intestines (duodenum >
jejunum > ileum) corresponds well with the longitudinal gradient
observed for toxicity and carcinogenicity in the mouse (duode-
num > jejunum > ileum) [1]. These data identify the duodenum as
the tissue with the highest levels of chromium of all measured
tissues including liver, and higher levels occurring in mice than
in rats for a given exposure level. In addition, the data collected
indicate a clear dose-dependent decrease of tissue iron concentra-
tions in the small intestines and liver in both species (See Appendix
A). The observation of signiﬁcantly increased iron content in eryth-
rocytes in mice exposed to the highest levels of Cr(VI) suggests that
some adaptation to altered iron status may be occurring. These
ﬁndings are likely related to the development of a microcytic ane-
mia in both species exposed to Cr(VI) [1].
Unlike the data for the small intestines, the data collected for
the oral cavity epithelium do not provide species-speciﬁc dose–re-
sponse concordance. Speciﬁcally, Cr tissue levels in the non-
responsive species for oral tumors (mouse) were generally higher
than those detected in the responsive species (rat) (Tables 2 and
3). These data suggest that factors other than the tissue dose of
chromium inﬂuence development of oral tumors in rats but not
in mice. For example, iron deﬁciency from consumption of a low
iron diet to produce low systemic iron levels has been shown to af-
fect oral cavity carcinogenesis in the rat [56]. Alternatively, it is
possible that the tissue data of the oral cavity are not reﬂective
of the target tissue cells and/or that species-speciﬁc differences
in tissue permeability changed over the course of the 2-year study.
The toxicokinetic data collected in our 90-day drinking water
studies are useful for supporting dose–response assessments for
chromium in terms of tissue dose measures. Due to analytical
inability to differentiate between Cr(III) and Cr(VI), only total chro-
mium can be measured in tissues. Therefore, the data collected for
the small intestines in this study can be used to assess the dose–re-
sponse relationship for toxicity and carcinogenicity in terms of to-
tal chromium tissue burden. However, to assess the dose–response
relationship in terms of internal dose measures more closely
related to the mode of action (e.g., area-under-the-curve or AUC
for Cr(VI), cumulative amount of Cr(VI) reduced within tissue), a
PBPK model is required.
The PBPK model developed here provides a good description of
Cr(III) and Cr(VI) toxicokinetics in rats and mice based upon avail-
able data. Model prediction fall within a factor of 3 or less than
measured values for approximately 90% and 80%, of the available
data points for rats and mice, respectively. For the rat, model pre-
dictions fell within a factor of 3 for 92% of available data points for
GI tract (oral, stomach, small intestines), for 93% of available data
points for systemic tissues (liver, kidney, bone, other), and 85% of
available data points for blood (whole blood, erythrocytes, plasma)
and urine. For the mouse, model predictions fell within a factor of 3
for 78% of available data points for GI tract, for 81% of available
data points for systemic tissues, and 74% of available data points
for blood and urine.
There are a number of sources of uncertainty in this model. For
example, it was assumed that the toxicokinetic data collected from
chromium picolinate studies [25] are useful for understanding the
toxicokinetics of Cr(III) generated from Cr(VI) exposures (i.e., from
reduced Cr(VI)). Although there is information that suggests that
absorption of chromium is greater for chromium picolinate than
chromium chloride at lower concentrations [57,58], several obser-
vations suggest the picolinate data are relevant for understanding
Cr(III) toxicokinetics following Cr(VI) exposure. First, chromium
absorption in the NTP picolinate study following chronic oral expo-sures [25] appears to be very low (well below 1%), and very near
estimates made for chronic exposures to chromium chloride based
on the tissue data of MacKenzie et al. [31]. Second, the low absorp-
tion of chromium, taken together with observations that the pico-
linate portion of the compound is well absorbed [25] suggests
substantial dissociation of chromium from picolinate occurs within
the GI lumen. Lastly, within a species, liver:kidney tissue concen-
tration ratios are consistent for chromium picolinate and Cr(VI)
exposures (Fig. 1). Additional sources of uncertainty are discussed
separately below for the GI and systemic components of the model.
Model predictions for the key patterns (liver:kidney and eryth-
rocyte:plasma ratios discussed in Section 3.1) are much improved
when compared to those for the O’Flaherty [17] model. Model sim-
ulations for the NTP cancer bioassay [1] resulted in predicted
liver:kidney ratios of approximately 0.3–0.4 for rats, compared to
a ratio of approximately 1.2 predicted by the O’Flaherty [17] mod-
el. Model predictions for NTP bioassay in mice [1] resulted in pre-
dicted liver:kidney ratios of approximately 1.0–1.2, but have no
basis for comparison because the O’Flaherty [17] model was not
parameterized for mice. Model predictions for the erythro-
cyte:plasma ratio are dose-dependent in both species (Fig. 12),
ranging from less than 1 at low doses to greater than 2 at high
doses. For comparison purposes, predictions for the erythro-
cyte:plasma ratio in rats by the O’Flaherty [17] model were
approximately 2 for all dose levels, even at very low Cr(VI) expo-
sure levels.
There are several sources of uncertainty in the model. First, the
model does not consider potential alterations in Cr(III) toxicokinet-
ics due to the effect of Cr(VI) treatment. Instead, it was assumed
that Cr(VI) exposures do not alter Cr(III) toxicokinetics. Given the
effects of Cr(VI) exposure on iron status and the potential interac-
tions between Cr(III) and iron (e.g., competition for transferrin
binding sites), this assumption may not be valid. For this reason,
additional studies that examine the toxicokinetics of Cr(III) in GI
tissues of animals with and without prior exposure to Cr(VI), with
the development of anemia and any adaptation, would be very
useful. Second, treatment related effects on processes that may af-
fect chromium toxicokinetics are not considered. Given that hyper-
plasia and altered villus structure [1,19,20,29] have been reported
in animals exposed to Cr(VI), it is likely that there are treatment re-
lated effects on transporter-mediated absorption and cell slough-
ing (processes R3 and R6 in Fig. 2) that are not included in the
model. At doses that are toxic to the villi, systemic absorption of
chromium is likely decreased with greater cell sloughing, while
compensatory proliferation of crypt cells likely contributes to the
carcinogenic process. Third, there are additional factors that may
contribute to lumen chromium reduction that are not considered
by the model. Although the reduction of Cr(VI) by rat and mouse
stomach contents (process R2a in Fig. 2) has been well character-
ized [21], and attempts were made to model the effect pH on
lumen reduction, it is unclear to what extent other factors (i.e., bile,
pancreatic secretions, intestinal secretions, and enzymatic activity)
might contribute to Cr(VI) reduction in the lumen of the small
intestines prior to absorption. Proximal portions of the small intes-
tine appear capable of luminal cysteine secretion [59], and cysteine
is known to reduce Cr(VI) [60]. Bacteria within intestinal lumen are
capable of reducing Cr(VI) [61,62]; however any chromium re-
duced by bacteria is likely to remain within the bacterial cells,
and therefore not available for absorption (i.e., not contributing
to Cr(III) concentration in the GI lumen). Fourth, data regarding
the reduction of Cr(VI) within GI tissues (process R2b in Fig. 2)
are lacking, requiring the use of erythrocyte Cr(VI) reduction data
as a surrogate. For this reason, additional information regarding
the rate of Cr(VI) reduction within duodenum, jejunum, and ileum
lumen and tissues would be useful. Furthermore, because there are
intracellular Cr(VI) reduction processes related to enzymatic (e.g.,
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ascorbate, reduced glutathione) (reviewed in Chiu et al. [63]; Nic-
kens et al. [64]), pathways for Cr(VI) reduction may have different
roles in the detoxiﬁcation/activation of chromium. Separate char-
acterization of these pathways may inform dose–response assess-
ments in terms of providing mechanistically-supported internal
dose measures. It may also be useful to characterize Cr(VI) reduc-
tion by cellular position within the crypt–villus axis, which corre-
sponds to enterocyte differentiation/maturation. As Shrivastava
et al. [65] reported, a gradient in Cr(VI) reduction capacity is pres-
ent along the rat intestinal villus (crypt cells < mid-villi < upper vil-
li). The sources of uncertainty discussed above serve to indicate
that the factors and processes affecting Cr(VI) reduction in the GI
tract may be more complex than modeled here. However, until
additional data are collected to quantify these factors, the default
approach for risk assessment purposes is to assume that they apply
equally to all species.
Sources of uncertainty in the systemic portion of the model are
to some extent of lesser importance than those identiﬁed for the GI
portion of the model because the effects of primary concern occur
at the portal of entry within the GI tract (i.e., prior to systemic up-
take of chromium into blood). However, characterizing systemic
tissue doses helps to better understand the ﬂux of chromium
through the GI tract, and may be useful for interpreting biomarkers
of exposure (e.g., erythrocyte:plasma ratio). Adequate information
regarding the toxicokinetics of protein-bound forms of chromium
[e.g., transferrin, low-molecular-weight protein(s)] or Cr(III)-bound
to peptides in the species of interest were not identiﬁed, requiring
some assumptions in the model that are likely oversimpliﬁcations
(e.g., uptake of chromium bound to low molecular weight pro-
tein(s) is negligible for all tissues except the kidney). For this rea-
son, tissue time-course data in rats and mice for bound forms
following i.v. injection would improve conﬁdence in tissue transfer
terms deﬁned in the systemic model.
Additional uncertainty stems from some simplifying assump-
tions made in the modeling of the rodent data. For example, for
the sake of simplicity exposures to Cr were assumed to be contin-
uous rather than episodic in nature. Because factors in the GI lu-
men such as content volume and pH remain relatively consistent
in rodents, even during periods of fasting, this assumption is not
expected to contribute signiﬁcant uncertainty to the modeling in
rodents. In humans, however, the timing of Cr(VI) exposure epidos-
es to relative to diurnal variation in these factors is expected to be a
much more important consideration. A second simplifying
assumption was adopted with respect to use of time-weighted
average values for dose and body weight for chronic exposures.
In the NTP studies [1,25], additional information are available
regarding changes in body weight and administered dose (based
on food and water consumption rates) over the course of the expo-
sure period. Including changes in dose and body weight in the
modeling might serve to improve model predictions for the early
time points in the NTP data, but is not expected to have a large im-
pact on estimates for the lifetime average estimates of internal
dose.
There are clear species differences between rats and mice rele-
vant to the toxicokinetics of chromium in the small intestines.
With respect to physiology, the small intestines comprise a larger
fraction of body weight in mice than rats (approximately 0.039
vs. 0.015); however, the jejunum comprises a much larger fraction
of the small intestines in rats than in mice (Table 4). Lumen vol-
umes expressed as a fraction of body weight are generally higher
in the mouse than the rat, except for the jejunum (Table 4). Transit
times for chromium in the intestinal lumen are considerably faster
(approximately 3.9-fold) in the mouse than rat, which results in
less time for competing processes (e.g., lumen Cr(VI) reduction,
absorption) to occur prior to reaching distal segments.PBPK model predictions for the fraction of chromium absorbed
are valence, dose, and species dependent. Absorption of Cr(III) and
Cr(VI) is predicted by themodel to be dose-dependent, with a smal-
ler fraction absorbed at higher doses than at lower doses. Themodel
predicts that the fraction of chromiumabsorbed in theNTP bioassay
for chromiumpicolinate [25] is nearly an order of magnitude higher
in rats than inmice (approximately 0.0002–0.001 vs. approximately
0.00002–0.0002). In contrast, model predictions for the fraction of
chromium absorbed in the NTP bioassay [1] and this study, which
reﬂects a mixture of chromium absorbed as both Cr(III) and Cr(VI),
are slightly higher in mice than in rats (0.004–0.008 vs. 0.003–
0.005). This suggests that despite faster transit times in mice, Cr(VI)
is absorbed to a greater extent in mice than in rats. For exposures to
Cr(VI), chromium is absorbed as a mixture of both Cr(III) (i.e., Cr(VI)
that has been reduced in the GI lumen) and Cr(VI). Model predic-
tions for the rat cancer bioassay are that approximately 89–93% of
the absorbed chromium was as Cr(VI) and approximately 7–11%
as Cr(III). Similarly, model predictions for the mouse cancer bioas-
say are that approximately 96–97% of the absorbed chromium
was as Cr(VI) and approximately 3–4% as Cr(III).
Themodel predicts that the cancer bioassay data of NTP [1] were
collected at Cr(VI) doses where saturable toxicokinetics may be
expected. At doses above 1 mg Cr(VI)/kg day (corresponding to
drinking water concentrations of approximately 5–6 mg Cr(VI)/L
in rodents), the reductive capacity of the GI lumen begins to become
depleted resulting in a greater fraction of Cr(VI) remaining in the lu-
men available for uptake into GI tissue. The fraction of total Cr
remaining as Cr(VI) in the GI lumen is higher in mice than in rats,
which can be attributed to higher transit rates inmice (i.e., less time
for reduction to occur in the stomach lumen), combined with fairly
similar rates and capacities for Cr(VI) reduction stomach contents
for both species [21]. Above 10 mg Cr(VI)/kg day, absorption of
Cr(VI) exhibits saturation. Amechanism for this effect on absorption
is not known, but plausibly could be related to the toxic response
(hyperplasia) elicited by Cr(VI) in the small intestines. Cr(VI) doses
in rats andmice that correspond approximately to current US drink-
ing water standard for total chromium [0.02 mg Cr(VI)/kg] are
well below those associated with saturable toxicokinetics. Further,
no changes in redox status or histopathologywere observed at these
low doses in either mice or rats [19,20].
The application of the PBPK model to human health risk assess-
ment will require a careful consideration of the mode of action for
the tumorigenic effects. For the mouse small intestines tumors, po-
tential candidate dose measures include those for Cr(VI) concen-
tration (e.g., in the small intestines lumen or tissue) or Cr(VI) ﬂux
(e.g., Cr(VI) leaving the stomach lumen or entering into small
intestines tissue, normalized to tissue volume). Alternatively ﬂux
estimates can be normalized to SI surface area as a means to
address point of contact effects. Selection of an appropriate dose
measure will also need to include a consideration of the conﬁdence
in the PBPK model predictions. There is reasonable conﬁdence in
model predictions for small intestines tissue concentrations of
Cr(VI) in rodents because they are grounded by observed measure-
ments made for total chromium.
The PBPK model presented here can be used to improve upon
default approaches used in human health risk assessment. Allome-
tric scaling of dose (body weight to the 3=4 power) serves as the de-
fault approach for interspecies extrapolation in risk assessment.
This approach invokes two key assumptions: (1) that tissue re-
sponse is proportionate to the concentration of parent chemical
in blood (i.e., species exposed to equivalent doses of a chemical
in terms of mg/kg3/4 day will experience equivalent concentrations
of the parent chemical in blood); and (2) that factors contributing
to the concentration of parent chemical in blood vary across spe-
cies scaled to a 3=4 power of bodyweight. With respect to mouse tu-
mors in the small intestines, the tissue response occurs prior to
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lates the ﬁrst assumption for allometric scaling of dose. With re-
spect to the second assumption, some of the factors contributing
to tissue dose do not vary across species in systematically predict-
able manner based on a 3=4 scaling factor. For example, there is a in-
verse relationship between gastrointestinal transit rate and the
fraction of unreduced Cr(VI) in the GI lumen. Additionally, there
are clear species differences in the relative size and lengths of
the small intestines (Table 4). In addition, species differences have
been reported for small intestines surface areas in rats and mice
[68,69], which may contribute to species differences in the relative
absorption of Cr(III) and Cr(VI) reported here. Furthermore, a num-
ber of estimated model parameters for Cr absorption and tissue
transfer were found to differ between rats and mice by more than
a factor of 5 (e.g., kmredgit, kmabs3s, vmabs6, kmabs3, kin6, kin-
tcrl, koutccrb; Tables 4 and 5), which may underly species differ-
ences in absorption and systemic distribution (i.e., liver:kidney
ratios discussed in Section 3.1). For these reasons, allometric scal-
ing of Cr(VI) dose to assess GI effects across species is not expected
to be reliable, and will result in invalid estimates of risk. By
accounting for key species differences and sources of saturable tox-
icokinetics, the rodent PBPKmodel present here, when used in con-
junction with a human PBPK model for Cr(VI), can be used by risk
assessors to provide a more robust characterization of the potential
risks associated with low-dose exposures of human populations to
Cr(VI).
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